Covered recipient · General Payments record
JOHN B CHAWLUK
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$273,850.93
- Reported across 774 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,500.00 | 2 |
| Travel and Lodging | $1,470.00 | 2 |
| Food and Beverage | $1,335.72 | 54 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $8,137.77 | 10 |
| EISAI INC. | $152.60 | 2 |
| UCB, Inc. | $87.86 | 3 |
| SK Life Science, Inc. | $83.55 | 3 |
| ACADIA Pharmaceuticals Inc | $81.22 | 3 |
| EMD Serono, Inc. | $60.30 | 2 |
| Otsuka America Pharmaceutical, Inc. | $56.83 | 3 |
| PFIZER INC. | $56.07 | 3 |
| Amneal Pharmaceuticals LLC | $54.81 | 2 |
| CSL Behring | $53.68 | 2 |
| Genentech USA, Inc. | $42.76 | 2 |
| Biogen, Inc. | $42.66 | 2 |
| Neurocrine BioSciences, Inc. | $40.21 | 2 |
| Celgene Corporation | $34.77 | 2 |
| Teva Pharmaceuticals USA, Inc. | $32.16 | 2 |
| Kyowa Kirin, Inc. | $23.88 | 1 |
| Medtronic, Inc. | $23.29 | 1 |
| Lilly USA, LLC | $22.74 | 1 |
| Axsome Therapeutics, Inc. | $22.03 | 1 |
| TG THERAPEUTICS, INC. | $21.33 | 1 |
| Xeris Pharmaceuticals, Inc. | $21.17 | 1 |
| CATALYST PHARMACEUTICALS, INC. | $20.20 | 1 |
| MDD US Operations, LLC | $17.92 | 1 |
| Alexion Pharmaceuticals, Inc. | $17.85 | 1 |
| Sandoz Inc. | $17.53 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $17.21 | 1 |
| LivaNova USA, Inc. | $17.18 | 1 |
| Lundbeck LLC | $16.25 | 1 |
| ARGENX US, INC. | $16.22 | 1 |
| Neurelis, Inc. | $13.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (58)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.